Cited by 30Diabetes Management and ResearchPancreatic function and diabetesRegulation of Appetite and Obesity

Modulation of β-adrenergic receptors in the ventromedial hypothalamus influences counterregulatory responses to hypoglycemia

Open access
Szepietowska, Barbara, Zhu, Wanling, Chan, Owen, Horblitt, Adam, Dziura, James, Sherwin, Robert S.·2011·Diabetes

Abstract

OBJECTIVE: Norepinephrine is locally released into the ventromedial hypothalamus (VMH), a key brain glucose-sensing region in the response to hypoglycemia. As a result, this neurotransmitter may play a role in modulating counterregulatory responses. This study examines whether norepinephrine acts to promote glucose counterregulation via specific VMH β-adrenergic receptors (BAR). RESEARCH DESIGN AND METHODS: Awake male Sprague-Dawley rats received, via implanted guide cannulae, bilateral VMH microinjections of 1) artificial extracellular fluid, 2) B2AR agonist, or 3) B2AR antagonist. Subsequently, a hyperinsulinemic-hypoglycemic clamp study was performed. The same protocol was also used to assess the effect of VMH delivery of a selective B1AR or B3AR antagonist. RESULTS: Despite similar insulin and glucose concentrations during the clamp, activation of B2AR in the VMH significantly lowered by 32% (P < 0.01), whereas VMH B2AR blockade raised by 27% exogenous glucose requirements during hypoglycemia (P < 0.05) compared with the control study. These changes were associated with alternations in counterregulatory hormone release. Epinephrine responses throughout hypoglycemia were significantly increased by 50% when the B2AR agonist was delivered to the VMH (P < 0.01) and suppressed by 32% with the B2AR antagonist (P < 0.05). The glucagon response was also increased by B2AR activation by 63% (P < 0.01). Neither blockade of VMH B1AR nor B3AR suppressed counterregulatory responses to hypoglycemia. Indeed, the B1AR antagonist increased rather than decreased epinephrine release (P < 0.05). CONCLUSIONS: Local catecholamine release into the VMH enhances counterregulatory responses to hypoglycemia via stimulation of B2AR. These observations suggest that B2AR agonists might have therapeutic benefit in diabetic patients with defective glucose counterregulation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db11-0432

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Szepietowska, B., Zhu, W., Chan, O., Horblitt, A., Dziura, J., & Sherwin, R. S.
Affiliations
Yale University (US)
Corresponding author
Sherwin, Robert S.
Venue
Diabetes
Published
2011-11-13
Volume
60
Issue
12
Pages
3154-3158
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2160721331
Cited by
30
References
25
Citations by year
2025: 1 · 2022: 1 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 1 · 2017: 1 · 2016: 1 · 2015: 1 · 2014: 4 · 2013: 8 · 2012: 4
FWCI
4.19
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • American Diabetes Association
  • Yale University
  • National Institute of Diabetes and Digestive and Kidney Diseases (R37DK020495)
  • Yale Liver Center
  • Yale Center for Clinical Investigation, Yale School of Medicine
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
beta2-adrenergic receptor, ventromedial hypothalamus, hypoglycemia, glucose counterregulation, norepinephrine, epinephrine, glucagon, beta1-adrenergic receptor, beta3-adrenergic receptor, hyperinsulinemic hypoglycemic clamp, glucose detection
MeSH terms
Formoterol Fumarate, Adrenergic beta-Antagonists, Animals, Blood Glucose, Epinephrine, Ethanolamines, Glucagon, Hypoglycemia, Imidazoles, Insulin, Male, Norepinephrine, Propanolamines, Receptors, Adrenergic, beta, Ventromedial Hypothalamic Nucleus, Glucose Clamp Technique, Rats, Sprague-Dawley, Rats, Adrenergic beta-2 Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review